Haleon Egypt: 20% Market Share & Local Manufacturing
- Haleon, a global leader in consumer health, has solidified its position in Egypt since its separation from GSK in July 2022.
- Alavi told Daily News Egypt that local production includes well-known brands like Sensodyne, Parodontax, Panadol, Otrivin, and Voltaren Emulgel.
- Local manufacturing has helped protect the company from global economic instability,including inflation,currency fluctuations,and supply chain issues,Alavi said.
Haleon dominates the Egyptian consumer health market, boasting over 20% share, a significant achievement discussed in News Directory 3’s insightful analysis. The company strategically manufactures essential brands locally, including Sensodyne and Panadol, bolstering a resilient supply chain and shielding itself from global economic instability. This commitment extends beyond market share; Haleon actively invests in self-care initiatives, fostering potential healthcare savings and enhancing product accessibility through tiered pricing strategies. Local production also highlights the importance of “consumer healthcare” in Egypt. Discover how Haleon’s long-term vision will shape the future of health in Egypt.
Haleon Strengthens Egypt Presence in Consumer Health Market
Updated June 02, 2025
Haleon, a global leader in consumer health, has solidified its position in Egypt since its separation from GSK in July 2022. Asif Alavi, general manager for North Africa at Haleon, said the company now controls more than 20% of Egypt’s consumer health market, with about 90% of its major brands manufactured locally.
Alavi told Daily News Egypt that local production includes well-known brands like Sensodyne, Parodontax, Panadol, Otrivin, and Voltaren Emulgel. This underscores Haleon’s dedication to a resilient supply chain and economic contributions through technology transfer and export capabilities. Egypt serves as a crucial regional export hub for the maghreb, Gulf countries, and Saudi Arabia.
Local manufacturing has helped protect the company from global economic instability,including inflation,currency fluctuations,and supply chain issues,Alavi said. “Our strategy has significantly minimized exposure to global shocks, enabling us to maintain stability and accessibility in the Egyptian market,” he noted.
Globally, Haleon is advancing its innovation pipeline, including a £130 million investment in a new Global Oral Health Innovation Center in Weybridge, UK, scheduled to open in 2027. The facility will support Haleon’s category leadership in oral health and accelerate R&D for key brands like Sensodyne, which Alavi described as resilient due to its therapeutic value and strong dentist recommendations—even during economic downturns.
Recognizing price sensitivity in emerging markets,Haleon has adopted a multi-format,tiered pricing strategy to ensure broad accessibility to its consumer healthcare products.
The company also promotes self-care as a key element of enduring healthcare.Alavi referenced research by the Global Self-Care Federation, estimating that self-care interventions have already saved $119 billion in global healthcare costs and generated $1.9 trillion in welfare gains.These figures are projected to increase to $179 billion and $2.8 trillion, respectively.
We are committed to being a core contributor to the Egyptian healthcare ecosystem—by making everyday health more accessible, inclusive, and sustainable.
What’s next
Looking ahead, Alavi confirmed Haleon’s long-term vision in Egypt, emphasizing the company’s commitment to making everyday health more accessible and sustainable.